Skip to Content

Posts tagged with "Clinical Trials"

  • Cancer

    Geron, And The Risk of Cancer Therapies

    Geron’s telomerase inhibitor compound, imetalstat, showed a lot of interesting results in vitro, and has been in Phase II trials all this year. Until now. The company announced this morning that the interim results of their breast-cancer trial are so unpromising that it’s been halted, and that lung cancer data aren’t looking good… Read More
  • Cardiovascular Disease

    Eli Lilly’s Drumbeat of Bad News

    Eli Lilly has been getting shelled with bad news recently. There was the not-that-encouraging-at-all failure of its Alzheimer’s antibody solanezumab to meet any of its clinical endpoints. But that’s the good news, since that (at least according to the company) it showed some signs of something in some patients. We can’t say that a… Read More
  • Alzheimer's Disease

    Lilly’s Solanezumab: A Miss or a Win?

    Lilly has reported results from its anti-amyloid antibody, solanezumab, and. . .well, it’s mixed. And it’s either quite good news, or quite bad. You make the call. The therapy missed its endpoints (both “cognitive and functional”, according to the company) in two clinical trials, so that’s clearly bad news. Progression… Read More
  • Clinical Trials

    Is Ampyra Any Good?

    I wrote here about Ampyra, the multiple sclerosis drug from Acorda Therapeutics, one that came close to the record for “simplest chemical matter in a marketed drug”. (As it happens, Biogen Idec is making sure that it doesn’t even have the title of “simplest drug for multiple sclerosis”, and the shadow of valproic acid… Read More
  • Cancer

    Does Aveo’s Tivozanib Work, or Not?

    What makes a cancer drug effective? What if it stops cancer from spreading when you give it to patients – is that effective, or not? This topic has come up around here before, but there may be a rather stark example of it unfolding with Aveo Pharmaceuticals and their drug tivozanib. Earlier this year, the… Read More
  • Alzheimer's Disease

    Bapineuzumab Still Does Not Work Against Alzheimer’s

    As expected (by all but the most relentlessly optimistic observers), the anti-Alzheimers antibody bapineuzumab has now failed in its most likely patient population. Results came out last night about from patients who do not carry the ApoE4 mutation, the only group that seemed to offer hope in earlier clinical trials. The therapy missed its endpoint… Read More
  • Clinical Trials

    When Is A Company Shading the Truth About Its Clinical Trials?

    I wanted to point out this fine piece by Adam Feuerstein, “How to Tell When a Drug Company Fibs About Clinical Trial Results”. The points he makes apply especially to small companies trying to stay afloat, but they can show up anywhere. You need to look at when the trial started (and thus how long… Read More
  • Alzheimer's Disease

    Bapineuzumab Does Not Work Against Alzheimer’s

    This long, long story may finally be coming to an end. Immune-based therapies against beta-amyloid (and the associated amyloid plaques) have been in development for many years now (an excellent review here), and Elan has been in the thick of it for most of that time. Phase II results for this antibody came out in… Read More
  • Business and Markets

    AstraZeneca Admits It Spent Too Much Money

    Looks like AstraZeneca’s internal numbers agree with Matthew Herper’s. The company was talking about its current R&D late last week, and this comment stands out: Discovery head Mene Pangalos told reporters on Thursday that mistakes had been in the past by encouraging quantity over quality in early drug selection. “If you look… Read More
  • Cardiovascular Disease

    The CETP Rogues Gallery

    Has there ever been a less structurally appealing class of drugs than the cholesteryl ester transfer protein (CETP) inhibitors? Just look at that bunch. From left to right, that’s Pfizer’s torcetrapib (which famously was the first to crash and burn back in 2006), Roche’s dalcetrapib (which was pulled earlier this year from the cli… Read More